Schrödinger (SDGR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual meeting scheduled for June 22, 2026, to be held virtually, with voting on four main proposals.
Proposals include election of three Class III directors, advisory vote on executive compensation, amendment to the 2022 Equity Incentive Plan, and ratification of KPMG LLP as auditor.
Board recommends voting in favor of all proposals.
Proxy materials are available online, and shareholders can vote via internet, phone, or mail.
Voting matters and shareholder proposals
Election of three Class III directors for three-year terms expiring in 2029.
Advisory, non-binding vote on executive compensation (say-on-pay).
Amendment to the 2022 Equity Incentive Plan to increase shares available by 3,000,000.
Ratification of KPMG LLP as independent auditor for fiscal year ending December 31, 2026.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board consists of ten members divided into three classes with staggered terms.
Majority of directors are independent per Nasdaq rules; only CEO and one co-founder are not independent.
Committees include audit, compensation, nominating and corporate governance, and drug discovery.
Board diversity and skills matrices disclosed, highlighting a range of backgrounds and expertise.
Regular stockholder engagement on governance and board structure.
Latest events from Schrödinger
- Q1 2026 saw 12% ACV growth, strong drug discovery revenue, and a major M&A milestone.SDGR
Q1 20266 May 2026 - Virtual meeting to vote on directors, compensation, equity plan, and auditor ratification.SDGR
Proxy filing28 Apr 2026 - 23% revenue growth to $255.9M, strong cash, and shift to hosted software drive future profitability.SDGR
Q4 202515 Apr 2026 - Strategic shift to hosted software, AI integration, and new products drive growth and industry impact.SDGR
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - Transition to ACV, new product launches, and materials science drive growth outlook.SDGR
Leerink Global Healthcare Conference 202610 Mar 2026 - Transition to hosted services and AI-driven innovation drive growth and partnerships in drug discovery.SDGR
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Q1 saw strong software growth, clinical progress, and advancing predictive tox initiatives.SDGR
Jefferies Global Healthcare Conference 20253 Feb 2026 - All proposals passed, with strategic focus on clinical milestones and platform expansion.SDGR
AGM 20243 Feb 2026 - Q2 revenue up 35% to $47.3M; predictive toxicology and clinical pipeline drive growth.SDGR
Q2 20242 Feb 2026